Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 68 | 2023 | 155 | 10.000 |
Why?
|
Adenocarcinoma | 43 | 2020 | 206 | 5.300 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 14 | 2023 | 71 | 2.720 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 27 | 2020 | 337 | 2.720 |
Why?
|
Chemotherapy, Adjuvant | 26 | 2020 | 99 | 2.250 |
Why?
|
Chemoradiotherapy | 11 | 2019 | 73 | 1.890 |
Why?
|
Radiation Oncology | 10 | 2023 | 17 | 1.870 |
Why?
|
Fluorouracil | 21 | 2015 | 76 | 1.820 |
Why?
|
Combined Modality Therapy | 49 | 2017 | 386 | 1.780 |
Why?
|
Pancreaticoduodenectomy | 23 | 2010 | 35 | 1.580 |
Why?
|
Brain Neoplasms | 10 | 2023 | 133 | 1.490 |
Why?
|
Radiotherapy, Adjuvant | 24 | 2014 | 67 | 1.380 |
Why?
|
Sarcoma | 7 | 2019 | 149 | 1.350 |
Why?
|
Deoxycytidine | 15 | 2020 | 39 | 1.330 |
Why?
|
Neoadjuvant Therapy | 9 | 2022 | 78 | 1.320 |
Why?
|
Humans | 157 | 2023 | 31059 | 1.200 |
Why?
|
Antimetabolites, Antineoplastic | 13 | 2012 | 31 | 1.190 |
Why?
|
Radiotherapy, Intensity-Modulated | 7 | 2023 | 34 | 1.090 |
Why?
|
Radiotherapy Dosage | 22 | 2023 | 119 | 1.010 |
Why?
|
Antineoplastic Agents | 14 | 2013 | 259 | 0.970 |
Why?
|
Radiotherapy, Conformal | 4 | 2023 | 19 | 0.900 |
Why?
|
Organs at Risk | 7 | 2016 | 15 | 0.860 |
Why?
|
Middle Aged | 80 | 2020 | 10235 | 0.850 |
Why?
|
Adult | 69 | 2020 | 8945 | 0.840 |
Why?
|
Survival Analysis | 29 | 2019 | 322 | 0.800 |
Why?
|
Aged | 71 | 2022 | 10077 | 0.800 |
Why?
|
Tumor Burden | 11 | 2017 | 33 | 0.790 |
Why?
|
Male | 88 | 2021 | 16488 | 0.780 |
Why?
|
Treatment Outcome | 35 | 2019 | 3808 | 0.780 |
Why?
|
Female | 84 | 2021 | 17005 | 0.760 |
Why?
|
Radiometry | 4 | 2012 | 39 | 0.740 |
Why?
|
Liver Neoplasms | 9 | 2016 | 121 | 0.740 |
Why?
|
Radiosurgery | 4 | 2023 | 38 | 0.720 |
Why?
|
Prognosis | 24 | 2020 | 924 | 0.690 |
Why?
|
CA-19-9 Antigen | 6 | 2017 | 6 | 0.620 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2000 | 33 | 0.610 |
Why?
|
Bone Marrow Transplantation | 10 | 2005 | 36 | 0.600 |
Why?
|
Pancreatectomy | 3 | 2016 | 13 | 0.590 |
Why?
|
Clinical Trials as Topic | 8 | 2010 | 331 | 0.580 |
Why?
|
Lung Neoplasms | 11 | 2011 | 690 | 0.580 |
Why?
|
Glioma | 5 | 2020 | 54 | 0.580 |
Why?
|
Common Bile Duct Neoplasms | 4 | 2007 | 4 | 0.580 |
Why?
|
Ampulla of Vater | 5 | 2008 | 7 | 0.570 |
Why?
|
Attention | 5 | 2000 | 145 | 0.540 |
Why?
|
Soft Tissue Neoplasms | 2 | 2014 | 59 | 0.530 |
Why?
|
Medical Illustration | 2 | 2012 | 17 | 0.490 |
Why?
|
Algorithms | 7 | 2015 | 416 | 0.480 |
Why?
|
Radiation Injuries | 4 | 2023 | 35 | 0.470 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 5 | 2011 | 356 | 0.470 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2005 | 45 | 0.470 |
Why?
|
Brachytherapy | 3 | 2016 | 49 | 0.470 |
Why?
|
Retrospective Studies | 25 | 2021 | 3664 | 0.450 |
Why?
|
Hodgkin Disease | 4 | 2003 | 20 | 0.450 |
Why?
|
Aged, 80 and over | 28 | 2020 | 5196 | 0.440 |
Why?
|
Cholangiocarcinoma | 4 | 2009 | 7 | 0.440 |
Why?
|
Breast Neoplasms | 4 | 2014 | 375 | 0.440 |
Why?
|
Survival Rate | 24 | 2017 | 407 | 0.420 |
Why?
|
Evidence-Based Medicine | 3 | 2016 | 216 | 0.410 |
Why?
|
Quality Assurance, Health Care | 4 | 2016 | 50 | 0.410 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2011 | 16 | 0.410 |
Why?
|
Whole-Body Irradiation | 5 | 2012 | 17 | 0.410 |
Why?
|
Bile Duct Neoplasms | 4 | 2009 | 8 | 0.400 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2009 | 7 | 0.390 |
Why?
|
Disease-Free Survival | 16 | 2017 | 208 | 0.390 |
Why?
|
Retroperitoneal Neoplasms | 3 | 2015 | 10 | 0.380 |
Why?
|
Guideline Adherence | 2 | 2011 | 68 | 0.380 |
Why?
|
Supratentorial Neoplasms | 4 | 2011 | 6 | 0.380 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2014 | 11 | 0.370 |
Why?
|
Duodenal Neoplasms | 4 | 2007 | 9 | 0.350 |
Why?
|
Cranial Irradiation | 1 | 2010 | 13 | 0.350 |
Why?
|
Limbic System | 1 | 2010 | 11 | 0.350 |
Why?
|
Proportional Hazards Models | 12 | 2021 | 367 | 0.340 |
Why?
|
Holography | 1 | 2009 | 2 | 0.340 |
Why?
|
Cisplatin | 4 | 2010 | 95 | 0.330 |
Why?
|
Radiotherapy | 7 | 2005 | 54 | 0.320 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2009 | 81 | 0.310 |
Why?
|
Carcinoma, Small Cell | 6 | 2005 | 73 | 0.310 |
Why?
|
Chemoradiotherapy, Adjuvant | 3 | 2014 | 17 | 0.310 |
Why?
|
Neoplasm Staging | 16 | 2017 | 404 | 0.310 |
Why?
|
Employment | 2 | 2018 | 43 | 0.300 |
Why?
|
Prospective Studies | 19 | 2022 | 1897 | 0.300 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 230 | 0.290 |
Why?
|
Electronics | 1 | 2007 | 9 | 0.290 |
Why?
|
Visual Perception | 2 | 2000 | 48 | 0.290 |
Why?
|
Lymphatic Metastasis | 8 | 2015 | 104 | 0.280 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2003 | 26 | 0.280 |
Why?
|
Rectal Neoplasms | 2 | 2021 | 23 | 0.270 |
Why?
|
Practice Guidelines as Topic | 4 | 2017 | 344 | 0.270 |
Why?
|
Tomography, X-Ray Computed | 8 | 2016 | 818 | 0.270 |
Why?
|
Radiology | 2 | 2016 | 22 | 0.270 |
Why?
|
Cyclophosphamide | 5 | 2003 | 58 | 0.270 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2011 | 230 | 0.260 |
Why?
|
Astrocytoma | 3 | 2020 | 25 | 0.260 |
Why?
|
Multivariate Analysis | 8 | 2015 | 344 | 0.260 |
Why?
|
Doxorubicin | 6 | 2019 | 70 | 0.260 |
Why?
|
Biomarkers, Tumor | 5 | 2010 | 216 | 0.260 |
Why?
|
Maximum Tolerated Dose | 2 | 2012 | 20 | 0.250 |
Why?
|
Time Factors | 10 | 2017 | 1679 | 0.230 |
Why?
|
Cancer Vaccines | 4 | 2011 | 14 | 0.230 |
Why?
|
Eye Movements | 4 | 2001 | 20 | 0.230 |
Why?
|
Brain Injuries | 1 | 2023 | 47 | 0.220 |
Why?
|
Orientation | 2 | 1995 | 8 | 0.220 |
Why?
|
Follow-Up Studies | 11 | 2018 | 1936 | 0.210 |
Why?
|
Celiac Plexus | 1 | 2022 | 2 | 0.200 |
Why?
|
Truth Disclosure | 1 | 2002 | 11 | 0.200 |
Why?
|
Cardiac Volume | 1 | 2022 | 5 | 0.200 |
Why?
|
Cancer Pain | 1 | 2022 | 5 | 0.200 |
Why?
|
Fixation, Ocular | 3 | 2000 | 8 | 0.200 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2022 | 20 | 0.200 |
Why?
|
Physician-Patient Relations | 1 | 2002 | 42 | 0.200 |
Why?
|
Carcinoid Tumor | 2 | 1995 | 9 | 0.200 |
Why?
|
Analysis of Variance | 7 | 2018 | 326 | 0.200 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2009 | 6 | 0.200 |
Why?
|
Radioimmunotherapy | 3 | 2003 | 4 | 0.190 |
Why?
|
Palliative Care | 6 | 2004 | 154 | 0.190 |
Why?
|
Consensus | 4 | 2016 | 112 | 0.190 |
Why?
|
Saccades | 3 | 1998 | 3 | 0.190 |
Why?
|
Dose-Response Relationship, Radiation | 4 | 2007 | 15 | 0.190 |
Why?
|
Immunotherapy | 4 | 2011 | 69 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 4 | 2021 | 189 | 0.180 |
Why?
|
Insulins | 1 | 2020 | 4 | 0.180 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2011 | 22 | 0.180 |
Why?
|
Movement | 1 | 2001 | 137 | 0.180 |
Why?
|
Reproducibility of Results | 5 | 2015 | 820 | 0.180 |
Why?
|
Disease Progression | 10 | 2012 | 832 | 0.180 |
Why?
|
Erlotinib Hydrochloride | 1 | 2020 | 19 | 0.180 |
Why?
|
United States | 7 | 2018 | 2376 | 0.170 |
Why?
|
Lymph Nodes | 2 | 2010 | 74 | 0.170 |
Why?
|
Memory | 1 | 2001 | 330 | 0.170 |
Why?
|
Mesna | 1 | 2019 | 3 | 0.160 |
Why?
|
Neoplasms | 3 | 2003 | 261 | 0.160 |
Why?
|
Ifosfamide | 1 | 2019 | 14 | 0.160 |
Why?
|
Organ Sparing Treatments | 1 | 2019 | 7 | 0.160 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 147 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2012 | 360 | 0.160 |
Why?
|
Prostatic Neoplasms | 4 | 2003 | 114 | 0.160 |
Why?
|
Lymphoma | 3 | 2009 | 46 | 0.160 |
Why?
|
Career Choice | 1 | 2018 | 31 | 0.160 |
Why?
|
Leg | 1 | 2019 | 51 | 0.160 |
Why?
|
Radiography | 4 | 2015 | 695 | 0.160 |
Why?
|
Breast | 2 | 2009 | 21 | 0.160 |
Why?
|
Arm | 1 | 2019 | 82 | 0.160 |
Why?
|
alpha-Fetoproteins | 1 | 1998 | 5 | 0.160 |
Why?
|
Extremities | 2 | 2013 | 33 | 0.160 |
Why?
|
Patient Selection | 4 | 2017 | 246 | 0.160 |
Why?
|
Iodine Radioisotopes | 1 | 1998 | 16 | 0.160 |
Why?
|
Research Design | 3 | 2009 | 219 | 0.150 |
Why?
|
Lymph Node Excision | 4 | 2010 | 27 | 0.150 |
Why?
|
Pitch Discrimination | 1 | 1998 | 2 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2012 | 28 | 0.150 |
Why?
|
Chi-Square Distribution | 5 | 2018 | 149 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2012 | 29 | 0.150 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2017 | 10 | 0.150 |
Why?
|
Arousal | 1 | 1998 | 45 | 0.150 |
Why?
|
Intracranial Arteriovenous Malformations | 1 | 2017 | 8 | 0.150 |
Why?
|
Lymphocytes | 1 | 2018 | 111 | 0.150 |
Why?
|
Digestive System Neoplasms | 1 | 1997 | 6 | 0.150 |
Why?
|
Sensitivity and Specificity | 3 | 2012 | 586 | 0.150 |
Why?
|
Neutrophils | 1 | 2018 | 120 | 0.150 |
Why?
|
Preoperative Care | 4 | 2015 | 144 | 0.150 |
Why?
|
Databases, Factual | 3 | 2021 | 353 | 0.140 |
Why?
|
Reaction Time | 5 | 2000 | 128 | 0.140 |
Why?
|
Stomach | 2 | 2015 | 19 | 0.140 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2016 | 7 | 0.130 |
Why?
|
Risk Factors | 9 | 2015 | 2587 | 0.130 |
Why?
|
Hepatectomy | 2 | 2015 | 58 | 0.130 |
Why?
|
Intestine, Small | 2 | 2015 | 34 | 0.130 |
Why?
|
Quality of Life | 3 | 2015 | 697 | 0.130 |
Why?
|
RecQ Helicases | 1 | 2015 | 1 | 0.130 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2015 | 12 | 0.130 |
Why?
|
Adolescent | 10 | 2011 | 2400 | 0.130 |
Why?
|
Polymorphism, Genetic | 1 | 2015 | 75 | 0.130 |
Why?
|
Color Perception | 1 | 1995 | 5 | 0.130 |
Why?
|
Postoperative Care | 4 | 2008 | 132 | 0.120 |
Why?
|
Liposarcoma | 1 | 2015 | 18 | 0.120 |
Why?
|
Neoplasm Metastasis | 4 | 2014 | 113 | 0.120 |
Why?
|
Animals | 3 | 2014 | 4713 | 0.120 |
Why?
|
Liver | 2 | 2012 | 184 | 0.120 |
Why?
|
Mental Recall | 1 | 1995 | 72 | 0.120 |
Why?
|
Receptor, ErbB-2 | 1 | 2014 | 49 | 0.120 |
Why?
|
Neural Inhibition | 1 | 1994 | 11 | 0.110 |
Why?
|
History, 21st Century | 1 | 2014 | 35 | 0.110 |
Why?
|
Health Status | 1 | 2015 | 239 | 0.110 |
Why?
|
History, 20th Century | 1 | 2014 | 70 | 0.110 |
Why?
|
Pancreaticojejunostomy | 2 | 2012 | 3 | 0.110 |
Why?
|
Internship and Residency | 1 | 2017 | 227 | 0.110 |
Why?
|
Paclitaxel | 4 | 2011 | 76 | 0.110 |
Why?
|
Edema | 1 | 2013 | 40 | 0.110 |
Why?
|
France | 1 | 2012 | 21 | 0.100 |
Why?
|
Celiac Artery | 1 | 2012 | 2 | 0.100 |
Why?
|
Mesenteric Artery, Superior | 1 | 2012 | 4 | 0.100 |
Why?
|
Aortography | 1 | 2012 | 10 | 0.100 |
Why?
|
Radiography, Abdominal | 1 | 2012 | 6 | 0.100 |
Why?
|
Anatomic Landmarks | 1 | 2012 | 7 | 0.100 |
Why?
|
Spinal Cord | 1 | 2012 | 107 | 0.100 |
Why?
|
Portal Vein | 1 | 2012 | 42 | 0.100 |
Why?
|
Capecitabine | 3 | 2017 | 6 | 0.100 |
Why?
|
Ossification, Heterotopic | 1 | 2011 | 41 | 0.090 |
Why?
|
Cohort Studies | 5 | 2017 | 2041 | 0.090 |
Why?
|
Kidney | 1 | 2012 | 181 | 0.090 |
Why?
|
Transplantation, Autologous | 5 | 2009 | 198 | 0.090 |
Why?
|
Transplantation, Homologous | 6 | 2005 | 296 | 0.090 |
Why?
|
Gastrectomy | 3 | 2005 | 34 | 0.090 |
Why?
|
Antibodies, Monoclonal | 2 | 2009 | 271 | 0.090 |
Why?
|
Distance Perception | 1 | 1990 | 1 | 0.090 |
Why?
|
Optical Illusions | 1 | 1990 | 1 | 0.090 |
Why?
|
Pancreatitis, Chronic | 1 | 2010 | 1 | 0.090 |
Why?
|
Form Perception | 1 | 1990 | 2 | 0.090 |
Why?
|
Illusions | 1 | 1990 | 4 | 0.090 |
Why?
|
Motion Perception | 1 | 1990 | 2 | 0.090 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2010 | 13 | 0.090 |
Why?
|
Weight Gain | 1 | 2010 | 70 | 0.090 |
Why?
|
Multicenter Studies as Topic | 3 | 2010 | 76 | 0.090 |
Why?
|
Elbow Joint | 1 | 2011 | 133 | 0.090 |
Why?
|
Immune System | 1 | 2009 | 25 | 0.090 |
Why?
|
Pilot Projects | 2 | 2023 | 427 | 0.090 |
Why?
|
DNA, Neoplasm | 2 | 2003 | 24 | 0.090 |
Why?
|
Mastectomy, Segmental | 1 | 2009 | 14 | 0.090 |
Why?
|
Maryland | 2 | 2007 | 8 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2009 | 46 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2010 | 244 | 0.080 |
Why?
|
Statistics, Nonparametric | 2 | 2015 | 143 | 0.080 |
Why?
|
Equilibrative Nucleoside Transporter 1 | 1 | 2008 | 1 | 0.080 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2014 | 29 | 0.080 |
Why?
|
Gastrointestinal Diseases | 2 | 2015 | 46 | 0.080 |
Why?
|
Esophageal Neoplasms | 2 | 2000 | 49 | 0.080 |
Why?
|
Pancreas | 3 | 2015 | 37 | 0.080 |
Why?
|
Recovery of Function | 1 | 2009 | 298 | 0.080 |
Why?
|
Orthopedic Procedures | 1 | 2011 | 329 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 3 | 1997 | 192 | 0.070 |
Why?
|
Hippocampus | 1 | 2010 | 284 | 0.070 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1987 | 1 | 0.070 |
Why?
|
Baltimore | 2 | 2004 | 15 | 0.070 |
Why?
|
Plasmacytoma | 1 | 1987 | 19 | 0.070 |
Why?
|
Hemibody Irradiation | 1 | 2007 | 2 | 0.070 |
Why?
|
Iridium Radioisotopes | 1 | 2007 | 3 | 0.070 |
Why?
|
Radiotherapy, High-Energy | 3 | 1997 | 7 | 0.070 |
Why?
|
Incidence | 1 | 2010 | 783 | 0.070 |
Why?
|
Cues | 2 | 2000 | 60 | 0.070 |
Why?
|
Hospitals, University | 2 | 2004 | 41 | 0.070 |
Why?
|
Graft vs Host Disease | 4 | 2001 | 59 | 0.070 |
Why?
|
Nose Neoplasms | 1 | 1987 | 42 | 0.070 |
Why?
|
Induction Chemotherapy | 2 | 2017 | 15 | 0.070 |
Why?
|
Heart | 1 | 2007 | 100 | 0.070 |
Why?
|
Leukemia | 1 | 1986 | 10 | 0.070 |
Why?
|
Risk Assessment | 2 | 2011 | 715 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2000 | 226 | 0.070 |
Why?
|
Lung | 1 | 2007 | 173 | 0.070 |
Why?
|
Etoposide | 4 | 2011 | 53 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2015 | 225 | 0.060 |
Why?
|
Hematopoietic Stem Cells | 2 | 1985 | 15 | 0.060 |
Why?
|
Phantoms, Imaging | 1 | 2005 | 41 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 3 | 0.060 |
Why?
|
Observer Variation | 2 | 2015 | 118 | 0.060 |
Why?
|
Societies, Medical | 2 | 2017 | 191 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2005 | 14 | 0.060 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 105 | 0.060 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2004 | 9 | 0.060 |
Why?
|
Equipment Design | 1 | 2005 | 188 | 0.060 |
Why?
|
Surveys and Questionnaires | 3 | 2018 | 1210 | 0.060 |
Why?
|
Mitomycin | 2 | 2001 | 12 | 0.060 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2004 | 19 | 0.060 |
Why?
|
Bacteria, Anaerobic | 1 | 2003 | 2 | 0.060 |
Why?
|
Leukocyte Count | 3 | 2018 | 93 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 24 | 0.060 |
Why?
|
Cognition | 2 | 2020 | 1429 | 0.060 |
Why?
|
Hypoxia | 1 | 2003 | 63 | 0.060 |
Why?
|
Diploidy | 1 | 2003 | 4 | 0.060 |
Why?
|
Androgen Antagonists | 1 | 2003 | 4 | 0.060 |
Why?
|
Flutamide | 3 | 2003 | 3 | 0.050 |
Why?
|
Goserelin | 3 | 2003 | 3 | 0.050 |
Why?
|
Drug Therapy | 1 | 2003 | 15 | 0.050 |
Why?
|
Cyclosporine | 2 | 1999 | 17 | 0.050 |
Why?
|
Delphi Technique | 1 | 2022 | 30 | 0.050 |
Why?
|
Practice Patterns, Physicians' | 1 | 2003 | 135 | 0.050 |
Why?
|
Respiration | 1 | 2022 | 35 | 0.050 |
Why?
|
Europe | 1 | 2001 | 80 | 0.050 |
Why?
|
Blood Transfusion | 1 | 2001 | 65 | 0.050 |
Why?
|
Brain | 2 | 2023 | 1800 | 0.050 |
Why?
|
Clinical Protocols | 2 | 1998 | 68 | 0.050 |
Why?
|
Crohn Disease | 1 | 2001 | 46 | 0.050 |
Why?
|
Treatment Failure | 2 | 1999 | 168 | 0.050 |
Why?
|
Blood Platelets | 2 | 1997 | 51 | 0.050 |
Why?
|
Professional Staff Committees | 1 | 2001 | 9 | 0.050 |
Why?
|
Hematopoiesis | 1 | 1981 | 13 | 0.050 |
Why?
|
Colitis, Ulcerative | 1 | 2001 | 71 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2002 | 111 | 0.050 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2001 | 24 | 0.050 |
Why?
|
Anastomosis, Surgical | 2 | 1997 | 41 | 0.050 |
Why?
|
Neuropsychological Tests | 2 | 2004 | 1317 | 0.050 |
Why?
|
Marital Status | 1 | 2019 | 14 | 0.040 |
Why?
|
Retroperitoneal Space | 3 | 2005 | 11 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2000 | 59 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2000 | 74 | 0.040 |
Why?
|
Interferon-gamma | 1 | 1999 | 111 | 0.040 |
Why?
|
Lymphoma, AIDS-Related | 1 | 1999 | 4 | 0.040 |
Why?
|
Population Density | 1 | 2018 | 7 | 0.040 |
Why?
|
Job Application | 1 | 2018 | 7 | 0.040 |
Why?
|
Cities | 1 | 2018 | 15 | 0.040 |
Why?
|
Schools, Medical | 1 | 2018 | 21 | 0.040 |
Why?
|
Antigens, CD34 | 1 | 1998 | 14 | 0.040 |
Why?
|
Consumer Behavior | 1 | 2018 | 20 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 1998 | 19 | 0.040 |
Why?
|
Regression Analysis | 2 | 2012 | 301 | 0.040 |
Why?
|
AIDS Dementia Complex | 1 | 1999 | 41 | 0.040 |
Why?
|
HIV Seropositivity | 1 | 1999 | 83 | 0.040 |
Why?
|
Psychophysics | 1 | 1998 | 5 | 0.040 |
Why?
|
Sound Localization | 1 | 1998 | 7 | 0.040 |
Why?
|
Infusions, Intra-Arterial | 1 | 1997 | 2 | 0.040 |
Why?
|
Remission Induction | 2 | 2010 | 104 | 0.040 |
Why?
|
Necrosis | 1 | 2017 | 32 | 0.040 |
Why?
|
Genetic Therapy | 1 | 1998 | 93 | 0.040 |
Why?
|
Vincristine | 3 | 2000 | 27 | 0.040 |
Why?
|
Mental Status Schedule | 2 | 2011 | 121 | 0.040 |
Why?
|
Bone Marrow Purging | 1 | 1997 | 3 | 0.040 |
Why?
|
Platelet Count | 1 | 1997 | 22 | 0.040 |
Why?
|
Blood Cells | 1 | 1997 | 6 | 0.040 |
Why?
|
Professional Practice Location | 1 | 2017 | 2 | 0.040 |
Why?
|
Censuses | 1 | 2017 | 5 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 409 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2017 | 10 | 0.040 |
Why?
|
Safety | 1 | 1997 | 50 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 1997 | 67 | 0.040 |
Why?
|
Esophagectomy | 1 | 1997 | 24 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 1998 | 115 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2011 | 270 | 0.040 |
Why?
|
Hypersensitivity, Delayed | 2 | 2011 | 19 | 0.040 |
Why?
|
ROC Curve | 1 | 2017 | 145 | 0.030 |
Why?
|
Neutropenia | 2 | 2012 | 23 | 0.030 |
Why?
|
Biopsy | 1 | 1997 | 249 | 0.030 |
Why?
|
Thrombocytopenia | 2 | 2012 | 31 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1997 | 91 | 0.030 |
Why?
|
Cognition Disorders | 1 | 2003 | 1057 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2016 | 71 | 0.030 |
Why?
|
Glycogen Synthase Kinase 3 beta | 1 | 2015 | 16 | 0.030 |
Why?
|
Pelvis | 2 | 2008 | 33 | 0.030 |
Why?
|
Etanidazole | 1 | 1995 | 1 | 0.030 |
Why?
|
Feeding and Eating Disorders | 1 | 2015 | 12 | 0.030 |
Why?
|
United Kingdom | 1 | 2015 | 53 | 0.030 |
Why?
|
Research Personnel | 1 | 2015 | 21 | 0.030 |
Why?
|
Peritoneal Cavity | 1 | 2015 | 3 | 0.030 |
Why?
|
Duodenum | 1 | 2015 | 10 | 0.030 |
Why?
|
Length of Stay | 1 | 1997 | 339 | 0.030 |
Why?
|
Actuarial Analysis | 2 | 1993 | 14 | 0.030 |
Why?
|
Nephrectomy | 1 | 2015 | 32 | 0.030 |
Why?
|
Benchmarking | 1 | 2015 | 46 | 0.030 |
Why?
|
Pattern Recognition, Visual | 1 | 1995 | 31 | 0.030 |
Why?
|
Alleles | 1 | 2015 | 236 | 0.030 |
Why?
|
Fatigue | 1 | 2015 | 65 | 0.030 |
Why?
|
Ethane | 1 | 1994 | 2 | 0.030 |
Why?
|
Nucleic Acid Conformation | 1 | 1994 | 3 | 0.030 |
Why?
|
DNA Damage | 1 | 1994 | 31 | 0.030 |
Why?
|
Cell Division | 1 | 1994 | 113 | 0.030 |
Why?
|
Genotype | 1 | 2015 | 428 | 0.030 |
Why?
|
Portal System | 1 | 1994 | 2 | 0.030 |
Why?
|
Oxidative Stress | 1 | 1994 | 134 | 0.030 |
Why?
|
Avitaminosis | 1 | 2013 | 1 | 0.030 |
Why?
|
Dumping Syndrome | 1 | 2013 | 1 | 0.030 |
Why?
|
Anorexia | 1 | 2013 | 4 | 0.030 |
Why?
|
Colon | 1 | 2015 | 163 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 1995 | 144 | 0.030 |
Why?
|
Diarrhea | 1 | 2013 | 47 | 0.030 |
Why?
|
Patient Care Team | 1 | 2015 | 152 | 0.030 |
Why?
|
Radioisotopes | 1 | 2013 | 13 | 0.030 |
Why?
|
Gadolinium | 1 | 2013 | 10 | 0.030 |
Why?
|
Radiation Effects | 1 | 1992 | 1 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 1992 | 7 | 0.030 |
Why?
|
Reoperation | 1 | 1997 | 952 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 31 | 0.030 |
Why?
|
Pancreatic Ducts | 2 | 2002 | 3 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2017 | 1134 | 0.030 |
Why?
|
Postoperative Complications | 3 | 2011 | 996 | 0.030 |
Why?
|
Body Burden | 1 | 2012 | 8 | 0.030 |
Why?
|
Recurrence | 2 | 2005 | 375 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 2 | 2002 | 13 | 0.030 |
Why?
|
Cause of Death | 1 | 2012 | 70 | 0.020 |
Why?
|
Biomarkers | 1 | 2015 | 734 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2012 | 59 | 0.020 |
Why?
|
Ocular Motility Disorders | 1 | 1991 | 2 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2003 | 430 | 0.020 |
Why?
|
Carboplatin | 1 | 2011 | 50 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2011 | 27 | 0.020 |
Why?
|
Sex Factors | 1 | 2012 | 508 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2011 | 46 | 0.020 |
Why?
|
Transfection | 1 | 2011 | 127 | 0.020 |
Why?
|
Reference Standards | 1 | 2010 | 32 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 105 | 0.020 |
Why?
|
Kinesthesis | 1 | 1990 | 3 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2010 | 4 | 0.020 |
Why?
|
Interferon-alpha | 1 | 2010 | 69 | 0.020 |
Why?
|
DNA | 1 | 2010 | 124 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2009 | 4 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2010 | 256 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2011 | 223 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 39 | 0.020 |
Why?
|
Rituximab | 1 | 2009 | 55 | 0.020 |
Why?
|
Drug Evaluation | 2 | 1986 | 54 | 0.020 |
Why?
|
Contracture | 1 | 2009 | 15 | 0.020 |
Why?
|
Depression | 1 | 2013 | 481 | 0.020 |
Why?
|
Organ Size | 1 | 2009 | 108 | 0.020 |
Why?
|
Inguinal Canal | 1 | 2008 | 1 | 0.020 |
Why?
|
Anus Neoplasms | 1 | 2008 | 8 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2008 | 28 | 0.020 |
Why?
|
DNA Methylation | 1 | 2010 | 132 | 0.020 |
Why?
|
Child | 2 | 2005 | 1428 | 0.020 |
Why?
|
Leucovorin | 2 | 2000 | 16 | 0.020 |
Why?
|
Rectum | 1 | 2008 | 66 | 0.020 |
Why?
|
Ilium | 1 | 2008 | 34 | 0.020 |
Why?
|
Psychomotor Performance | 1 | 1990 | 219 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2008 | 329 | 0.020 |
Why?
|
Staining and Labeling | 1 | 1987 | 22 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 1987 | 39 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 1321 | 0.020 |
Why?
|
Nasal Cavity | 1 | 1987 | 37 | 0.020 |
Why?
|
Lomustine | 1 | 1986 | 2 | 0.020 |
Why?
|
Procarbazine | 1 | 1986 | 3 | 0.020 |
Why?
|
Methotrexate | 1 | 1986 | 43 | 0.020 |
Why?
|
Amsacrine | 1 | 1986 | 2 | 0.020 |
Why?
|
Aminoacridines | 1 | 1986 | 2 | 0.020 |
Why?
|
Blood Cell Count | 1 | 1986 | 17 | 0.020 |
Why?
|
Bone Marrow | 1 | 1986 | 81 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1986 | 443 | 0.020 |
Why?
|
Cardiac Output | 1 | 1985 | 23 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 79 | 0.020 |
Why?
|
Bias | 1 | 2005 | 36 | 0.020 |
Why?
|
Area Under Curve | 1 | 2005 | 70 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 1985 | 59 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 2005 | 41 | 0.020 |
Why?
|
Random Allocation | 1 | 1985 | 147 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2005 | 100 | 0.020 |
Why?
|
Young Adult | 1 | 2011 | 2057 | 0.020 |
Why?
|
Probability | 1 | 2005 | 99 | 0.020 |
Why?
|
HIV Infections | 1 | 1991 | 886 | 0.010 |
Why?
|
Cesium Radioisotopes | 1 | 2003 | 1 | 0.010 |
Why?
|
Clostridium | 1 | 2003 | 3 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2003 | 23 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2003 | 40 | 0.010 |
Why?
|
Sampling Studies | 1 | 2003 | 29 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2003 | 75 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2003 | 91 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2003 | 271 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 304 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2003 | 40 | 0.010 |
Why?
|
Quinolones | 1 | 2003 | 21 | 0.010 |
Why?
|
Child, Preschool | 1 | 2005 | 689 | 0.010 |
Why?
|
Oncogenes | 1 | 2002 | 13 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 144 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2003 | 464 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2003 | 146 | 0.010 |
Why?
|
Smad4 Protein | 1 | 2001 | 2 | 0.010 |
Why?
|
Trans-Activators | 1 | 2001 | 28 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2003 | 555 | 0.010 |
Why?
|
Lymphocyte Depletion | 1 | 2001 | 6 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1981 | 5 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2001 | 11 | 0.010 |
Why?
|
Consumer Product Safety | 1 | 2001 | 4 | 0.010 |
Why?
|
Granulocytes | 1 | 1981 | 23 | 0.010 |
Why?
|
Dipyridamole | 1 | 2000 | 4 | 0.010 |
Why?
|
Organizational Objectives | 1 | 2001 | 23 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 18 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2000 | 97 | 0.010 |
Why?
|
Forecasting | 1 | 2001 | 115 | 0.010 |
Why?
|
Intestinal Perforation | 1 | 2000 | 4 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2003 | 782 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 1981 | 246 | 0.010 |
Why?
|
Monocytes | 1 | 1981 | 115 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2000 | 13 | 0.010 |
Why?
|
Intestinal Fistula | 1 | 2000 | 7 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2000 | 16 | 0.010 |
Why?
|
Colonic Diseases | 1 | 2000 | 15 | 0.010 |
Why?
|
Intestinal Obstruction | 1 | 2000 | 14 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 87 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2001 | 274 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 33 | 0.010 |
Why?
|
Prednisone | 1 | 2000 | 69 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2000 | 78 | 0.010 |
Why?
|
Signal Transduction | 1 | 2001 | 498 | 0.010 |
Why?
|
Transplantation Chimera | 1 | 1998 | 2 | 0.010 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 1998 | 4 | 0.010 |
Why?
|
Morbidity | 1 | 1999 | 65 | 0.010 |
Why?
|
Mice | 1 | 2003 | 1681 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2000 | 120 | 0.010 |
Why?
|
Vaccination | 1 | 1998 | 47 | 0.010 |
Why?
|
Graft Rejection | 1 | 1998 | 75 | 0.010 |
Why?
|
Contraindications | 1 | 1998 | 42 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 1998 | 139 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2001 | 1506 | 0.010 |
Why?
|
False Positive Reactions | 1 | 1997 | 36 | 0.010 |
Why?
|
Genes, p53 | 1 | 1997 | 16 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1997 | 18 | 0.010 |
Why?
|
Gastrostomy | 1 | 1996 | 8 | 0.010 |
Why?
|
Jejunostomy | 1 | 1996 | 8 | 0.010 |
Why?
|
Case-Control Studies | 1 | 1998 | 661 | 0.010 |
Why?
|
Dexamethasone | 1 | 1996 | 47 | 0.010 |
Why?
|
Lipid Peroxidation | 1 | 1994 | 9 | 0.010 |
Why?
|
Free Radicals | 1 | 1994 | 9 | 0.010 |
Why?
|
Breath Tests | 1 | 1994 | 11 | 0.010 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1994 | 12 | 0.010 |
Why?
|
Mutation | 1 | 1997 | 407 | 0.010 |
Why?
|
Carmustine | 1 | 1993 | 5 | 0.010 |
Why?
|
Ferritins | 1 | 1993 | 9 | 0.010 |
Why?
|
Yttrium Radioisotopes | 1 | 1993 | 11 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 1993 | 55 | 0.010 |
Why?
|
Pursuit, Smooth | 1 | 1991 | 2 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 1991 | 224 | 0.010 |
Why?
|